The Dirty Secret of Genetic Testing: We're Still Not Sure What "Normal" Looks Like
By Sean Captain,
Fast Company
| 03. 04. 2016
Untitled Document
Getting a full readout of your entire genetic sequence promises to radically alter how we monitor our health, providing advanced warning of cancer and other diseases we may suffer and our chances of passing on those ailments. Clinical genetic testing firm Illumina is valued at nearly $23 billion, for example, while direct-to-consumer offering 23andMe is at about $1 billion. Meanwhile, the price for so-called whole genome sequencing has dropped to about $1,000.
But such whole-genome sequencing currently over-promises in several ways. One of them is a false sense of what constitutes a "normal" genome with which to compare someone's results. (The U.S. government's National Institutes of Health provides a narrow, widely used model.) The promise is best if you're white, and drops off fast for other ethnicities, like people of African origin. That’s because we simply don't have easy access to enough reference genomes, from a big enough variety of people, to understand the range of normal. Nor is there much willingness for companies that analyze genomes to look at all the varieties that are out there...
Related Articles
By Annika Inampudi, Science | 07.10.2025
Before a baby in the United States reaches a few days old, doctors will run biochemical tests on a few drops of their blood to catch certain genetic diseases that need immediate care to prevent brain damage or other serious...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Elizabeth Dwoskin and Yeganeh Torbati, The Washington Post | 07.16.2025
A group of well-heeled, 30-something women sat down to dinner last spring at a table set with pregnancy-friendly mocktails and orchids, ready to hear a talk about how to optimize their offspring.
Noor Siddiqui, the founder of an embryo-screening start-up...
By Suzanne O'Sullivan, New Scientist | 07.09.2025
Rare diseases are often hard to spot. They can evade detection until irreversible organ damage or disability has already set in. Last month, in the hope of preventing just this type of harm, the UK’s health secretary, Wes Streeting, announced...